CIHI: On December 17, the Canadian Institute for Health Information (CIHI) published statistics1 on drug spending, finding that in 2018, around 40% of drug spending was spent on 2% of beneficiaries. Out of this 2%, three out of five individuals used a drug therapy that cost $10,000 or more per year (e.g. antivirals or biologics for rheumatoid arthritis/Crohn’s disease). The top increases in drug spending over the past 5 years were for drug classes with average annual costs of $10,000 or more.
PMPRB Meds Entry Watch: In January 2020, the PMPRB released the Meds Entry Watch 2018, which analyzes information about medicines approved by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and/or Health Canada in 2017 and 2018.
Consistent with the CIHI report, one of the key findings is the continued upward trend in the entry of high-cost products (such as orphan drugs and oncology products), with nearly two thirds of the medicines approved internationally in 2017 having treatment costs over $10,000 per year, or $5,000 per 28-day cycle for oncology medicines.
References
1. Link to the original source is no longer available. See the 2019 report for more details.
Related Publications & Articles
-
CDA update: new five-year strategic plan and position statement on using AI in health technology assessments
On April 15, 2025 Canada’s Drug Agency (CDA) released its new five-year strategic plan, Insight to Impact 2025-2030.Read More -
Updated PMPRB Guidelines expected in summer 2025 and NPDUIS releases ninth edition of the Meds Entry Watch Report
In the Patented Medicine Prices Review Board (PMPRB)’s June 2025 NEWSletter, Acting Chairperson Anie Perrault confirms that the PMPRB plans on publishing its final Guidelines in summer 2025.Read More -
Update on biosimilars in Canada – June 2025
This article provides an update on developments in the biosimilar space in Canada—regulatory, approvals, pending submissions, litigation, and market access.Read More